Key result
Plasma TSG-6 levels were significantly increased in dilated cardiomyopathy patients with heart failure and correlated with cardiac function, myocardial fibrosis, and prognosis (P<0.001).
Why the study?
The clinical correlation between TSG-6 protein and dilated cardiomyopathy patients with heart failure had not been reported.
Cohort (n=129)
p-value: p=<0.001
Plasma TSG-6 levels are significantly elevated in DCM patients with heart failure and may serve as a novel biomarker for cardiac function, myocardial fibrosis, and prognosis.
TSG-6 levels may predict prognosis in ACS; hypothesis-generating and requires validation before clinical use.
OBJECTIVES: Tumor necrosis factor α stimulated gene 6 (TSG-6) protein is an inflammation-inducing protein. In recent years, TSG-6 protein has been found to play an anti-inflammatory and anti-fibrosis role in a variety of disease models. The level of TSG-6 protein in circulating blood is considered to be a biological indicator for the evaluation of acute coronary syndrome, severe infection, and other diseases, and it is closely related to the prognosis. The clinical correlation between TSG-6 protein and dilated cardiomyopathy (DCM) patients with heart failure has not been reported. This study aims to investigate the changes of plasma TSG-6 protein levels in cardiomyopathy patients with heart failure and its correlation with cardiac function, myocardial fibrosis, and prognosis. METHODS: Based on the prospective studies, a number of 90 DCM patients with heart failure were selected as a DCM heart failure group from Dec.1, 2019 to Sept.1, 2020. Thirty-nine healthy people were served as a control group. Plasma TSG-6, Collagen Ⅰ, Collagen III, and α-smooth muscle actin (α-SMA) were measured with ELISA test. Echocardiography was used to evaluate the structure and function of the heart. DCM patients with heart failure were followed up for 3 months. The patients were assigned into 2 groups according to whether they had major adverse cardiovascular events (MACE). The general clinical data, plasma TSG-6, Collagen Ⅰ, Collagen III, and α-SMA protein levels were compared between the control group and the DCM heart failure group. At the same time, the correlation between plasma TSG-6 protein level and cardiac function grade, myocardial fibrosis or prognosis of patients in the DCM heart failure group was analyzed. RESULTS: <0.001). CONCLUSIONS: The plasma levels TSG-6 in DCM patients with heart failure increase significantly, and the plasma levels TSG-6 could be used as a new predictor for cardiac function, myocardial fibrosis, and prognosis.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) conducted a cohort in Dilated cardiomyopathy (DCM) with heart failure (n=129). Plasma TSG-6 protein levels vs. Healthy controls was evaluated on Cardiac function, myocardial fibrosis, and prognosis (MACE) (p=<0.001). Plasma TSG-6 levels were significantly increased in dilated cardiomyopathy patients with heart failure and correlated with cardiac function, myocardial fibrosis, and prognosis (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: